StockData
Praxis Precision Medicines, Inc. logo

Praxis Precision Medicines, Inc. (PRAX) company profile

PRAXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30
$305.06−5.21 (-1.68%)

Close on Nov 17, 2026Market cap $8.52BP/E –Yield –

About Praxis Precision Medicines

Pharmaceutical Preparations, SIC 2834

The biopharmaceutical company specializes in developing precision therapies for central nervous system (CNS) disorders caused by imbalances in neuronal excitation and inhibition. Leveraging human genetic insights from epilepsies, the enterprise discovers and develops therapies using two proprietary platforms: Cerebrum, which focuses on small molecules, and Solidus, an antisense oligonucleotide engine. Its primary clinical-stage pipeline comprises small molecule candidates such as ulixacaltamide, vormatrigine, and relutrigine, as well as the oligonucleotide candidate elsunersen. The company creates these targeted therapeutics for individuals diagnosed with movement disorders, such as essential tremor, alongside severe genetic conditions like developmental and epileptic encephalopathies and common adult epilepsies.

The organization conducts clinical trials and development initiatives across diverse international territories by engaging a global network of contract research organizations and scientific collaborators. Additionally, the company maintains regional development and commercialization partnerships, including an agreement spanning China, Hong Kong, Macau, and Taiwan. The provided text does not disclose the location of the corporate headquarters.

Summary of the business section of Praxis Precision Medicines's latest annual report, written by StockData.

Company profile

Company

Legal name
Praxis Precision Medicines, Inc.
Headquarters
Boston, MA
Address
99 High Street, 30th Floor 02110
Phone
(617) 300-8460
Employees
168, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Ernst & Young LLP, Boston, Massachusetts

Stock & identifiers

Ticker
PRAX
Exchange
Nasdaq
IPO date
Oct 16, 2020
Shares outstanding
28M, Jul 31, 2026
Public float
$883.20M, Jun 30, 2025
Filer category
Large accelerated filer
Stock splits
1-for-15 reverse, Nov 29, 2023
SEC CIK
1689548
CUSIP
74006W207
ISIN
US74006W2070
FIGI
BBG00W9LF2G5
Share class FIGI
BBG00W9LF2H4
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Marcio SouzaChief Executive Officer, Director56,495
Timothy Edwin KellyChief Financial Officer31,167
Megan SniecinskiChief Operating Officer28,664
Lauren MastrocolaPrincipal Accounting Officer13,573
Alex NemiroffGeneral Counsel and Secretary26,011
Jill DeSimoneDirector13,807
Merit Ester CudkowiczDirector1,371
Jeffrey B. KindlerDirector2,537
William D. YoungDirector3,269
Stuart A. ArbuckleDirector2,537
Gregory NordenDirector1,559
Dean J. MitchellDirector18,622
Jeffrey ChodakewitzDirector1,371

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$8.71M$55.53M$3.02M$36$125
FY2024$13.43M$20.64M$3.98M$9$93
FY2023$2.12M$1.40M$933.45K$3$94
FY2022$6.03M-$17.64M$2.45M$4$90
FY2021$10.91M-$62.15M$4.12M$36$100

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
Marcio Souza
President and Chief Executive Officer
$659.20K$2.37M$3.69M$1.48M$507.00K$8.71M-35%
Timothy Kelly
Chief Financial Officer
$526.85K$789.38K$1.23M$632.22K$22.38K$3.20M-21%
Alex Nemiroff
General Counsel
$456.23K$710.44K$1.11M$547.47K$22.31K$2.84M-27%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Oct 16, 2020
Offer price
$19.00
Securities offered
10,000,000
Gross proceeds
$190.00M
Exchange
Nasdaq
First trading day
Oct 16, 2020
First-day close
$27.80+46.3%
Lock-up ends (est.)
Apr 14, 2021

“Our common stock has been approved for listing on The Nasdaq Global Select Market under the symbol “PRAX.” The initial public offering price of our common stock is $19.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of February 16, 2026, we have 168 employees and plan to continue to grow as we advance the potential of our pipeline.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?